Ductal Carcinoma in Situ of the Breast
January 2024 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Ductal Carcinoma in Situ of the Breast abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Ductal Carcinoma in Situ of the Breast. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Ductal Carcinoma in Situ of the Breast. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Ductal Carcinoma in Situ of the Breast every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study.
Authors:Schmitz RSJM, van den Belt-Dusebout AW, Clements K, Ren Y, Cresta C, Timbres J, Liu YH, Byng D, Lynch T, Menegaz BA, Collyar D, Hyslop T, Thomas S, Love JK, Schaapveld M, Bhattacharjee P, Ryser MD, Sawyer E, Hwang ES, Thompson A, Wesseling J, Lips EH, Schmidt MK
Institution:Division of Molecular Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 Amsterdam, Netherlands.; Division of Molecular Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 Amsterdam, Netherlands mk.schmidt@nki.nl.
Journal:BMJ. 2023 Oct 30;383:e076022. doi: 10.1136/bmj-2023-076022.

2:Clinical presentations and outcomes of young women aged <40 yrs with Ductal carcinoma in situ.
Authors:Yan Z, Ngeow J, Allen J, Lim GH
Institution:Breast Department, KK Women's and Children's Hospital, Singapore.
Journal:Breast Dis. 2023;42(1):299-303. doi: 10.3233/BD-230018.

3:Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial).
Authors:Kuo SH, Tseng LM, Chen ST, Sagara Y, Chang YC, Yeh HT, Kuo YL, Hung CC, Lu TP, Lee YH, Toi M, Huang CS
Institution:Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, No. 7, Chung-Shan South Rd, Taipei, Taiwan. huangcs@ntu.edu.tw.
Journal:BMC Cancer. 2023 Sep 14;23(1):865. doi: 10.1186/s12885-023-11291-6.

4:Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial.
Authors:Schmitz RSJM, Engelhardt EG, Gerritsma MA, Sondermeijer CMT, Verschuur E, Houtzager J, Griffioen R, Retèl V, Bijker N, Mann RM, van Duijnhoven F, Wesseling J, Bleiker EMA
Institution:Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Family Cancer Clinic, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; Department of Clinical Genetics, Leiden University Medical Center, Leiden, Netherlands. Electronic address: e.bleiker@nki.nl.
Journal:Eur J Cancer. 2023 Oct;192:113276. doi: 10.1016/j.ejca.2023.113276. Epub 2023 Aug 4.

5:Estrogen Receptor-negative Ductal Carcinoma In Situ (DCIS) of the Breast - an Institutional Review of Outcomes.
Authors:Zabrocka E, Newman B, Levey G, Sweeney K, Oentoro J, Ryu S, Stessin A
Institution:Department of Radiation Oncology, Stony Brook University, Stony Brook, NY, U.S.A.; alexander.stessin@stonybrookmedicine.edu.
Journal:Anticancer Res. 2023 Sep;43(9):4031-4036. doi: 10.21873/anticanres.16591.

6:Outcome of different radiotherapy strategies after breast conserving surgery in patients with ductal carcinoma in situ (DCIS).
Authors:Wärnberg F, Wadsten C, Karakatsanis A, Olofsson Bagge R, Holmberg E, Lindman H, Sawyer E, Vicini F, Mann GB, Karlsson P
Institution:Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Journal:Acta Oncol. 2023 Sep;62(9):1045-1051. doi: 10.1080/0284186X.2023.2245552. Epub 2023 Aug 12.

7:Mastectomy margins for ductal carcinoma-in-situ (DCIS): 18 Years of follow-up.
Authors:ElSherif A, Freyvogel Ramirez M, Moore EC, Dietz JR, Tu C, Valente SA
Institution:Division of Breast Surgery, Department of General Surgery, Cleveland Clinic, Cleveland, OH, United States. Electronic address: Valents3@ccf.org.
Journal:Am J Surg. 2023 Nov;226(5):646-651. doi: 10.1016/j.amjsurg.2023.07.012. Epub 2023 Jul 14.

8:Women's views about current and future management of Ductal Carcinoma in Situ (DCIS): A mixed-methods study.
Authors:Nickel B, McCaffery K, Jansen J, Barratt A, Houssami N, Saunders C, Spillane A, Rutherford C, Stuart K, Robertson G, Dixon A, Hersch J
Institution:Faculty of Medicine and Health, Wiser Healthcare, Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia.
Journal:PLoS One. 2023 Jul 21;18(7):e0288972. doi: 10.1371/journal.pone.0288972. eCollection 2023.

9:Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact.
Authors:Schandiz H, Park D, Kaiser YL, Lyngra M, Talleraas IS, Geisler J, Sauer T
Institution:Department of Pathology, Akershus University Hospital, Lorenskog, Norway. hschandiz@gmail.com.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Campus AHUS, Oslo, Norway.
Journal:Breast Cancer Res Treat. 2023 Sep;201(2):329-338. doi: 10.1007/s10549-023-07016-9. Epub 2023 Jul 15.

10:The long-term psychosocial consequences of screen-detected ductal carcinoma in situ and invasive breast cancer.
Authors:Gram EG, Manso TFR, Heleno B, Siersma V, Á Rogvi J, Brodersen JB
Institution:Center for General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark; Primary Health Care Research Unit, Region Zealand, Denmark. Electronic address: emma.gram@sund.ku.dk.; Center for General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark; Primary Health Care Research Unit, Region Zealand, Denmark; Research Unit for General Practice, Department of Community Medicine, Faculty of Health Sciences, UiT the Arctic University of Norway, Tromso, Norway.
Journal:Breast. 2023 Aug;70:41-48. doi: 10.1016/j.breast.2023.06.003. Epub 2023 Jun 7.

11:Should low-risk DCIS lose the cancer label? An evidence review.
Authors:Ma T, Semsarian CR, Barratt A, Parker L, Pathmanathan N, Nickel B, Bell KJL
Institution:School of Public Health, The University of Sydney, Sydney, NSW, 2006, Australia. katy.bell@sydney.edu.au.
Journal:Breast Cancer Res Treat. 2023 Jun;199(3):415-433. doi: 10.1007/s10549-023-06934-y. Epub 2023 Apr 19.

12:Outcomes of DCIS treated with breast conserving surgery without radiotherapy on recurrence, survival, and health-related quality of life.
Authors:Fitzpatrick SE, Eaton M, McLeay W, Dean NR
Institution:Department of Plastic and Reconstructive Surgery, Flinders Medical Centre, Adelaide, South Australia, Australia.
Journal:ANZ J Surg. 2023 Sep;93(9):2208-2213. doi: 10.1111/ans.18459. Epub 2023 Apr 16.

13:Positive surgical margins after breast-conserving surgery for ductal carcinoma in-situ: does histologic grade or estrogen receptor status matter?
Authors:Fauveau LR, Dao TN, Wallace LB, Mamawala MK, Obaid A, Waddimba AC, Grant MD
Institution:Division of Surgical Oncology, Department of Surgery, Baylor University Medical Center, 3410 Worth Street, Suite 235, Dallas, TX, 75246, USA. LindseyFauveau@yahoo.com.
Journal:Breast Cancer Res Treat. 2023 Jun;199(2):215-220. doi: 10.1007/s10549-023-06905-3. Epub 2023 Apr 7.

14:Imaging findings for response evaluation of ductal carcinoma in situ in breast cancer patients treated with neoadjuvant systemic therapy: a systematic review and meta-analysis.
Authors:Ploumen RAW, de Mooij CM, Gommers S, Keymeulen KBMI, Smidt ML, van Nijnatten TJA
Institution:Department of Surgery, Maastricht University Medical Centre+, Maastricht, The Netherlands. r.ploumen@maastrichtuniversity.nl.; GROW - School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.
Journal:Eur Radiol. 2023 Aug;33(8):5423-5435. doi: 10.1007/s00330-023-09547-7. Epub 2023 Apr 5.

15:Clinical Outcomes of Conservative Treatment for Low-Risk Ductal Carcinoma in Situ: A Systematic Review and Pooled Analysis.
Authors:Co M, Cheng KCK, Yeung YH, Lau KC, Qian Z, Wong CM, Wong BY, Sin ELK, Wong HYS, Ma CH
Institution:Center for Education and Training, Department of Surgery, University of Hong Kong, Hong Kong; Division of Breast Surgery, Queen Mary Hospital, Hong Kong. Electronic address: mcth@hku.hk.; Center for Education and Training, Department of Surgery, University of Hong Kong, Hong Kong.
Journal:Clin Oncol (R Coll Radiol). 2023 Apr;35(4):255-261. doi: 10.1016/j.clon.2023.01.019. Epub 2023 Feb 1.

16:Efficacy and safety of endocrine therapy after mastectomy in patients with hormone receptor positive breast ductal carcinoma in situ: Retrospective cohort study.
Authors:Niu N, Zhang Y, Bai Y, Wang X, Yan S, Song D, Xu H, Liu T, Hua B, Zhang Y, Liu J, Qiao X, Liu J, Zheng X, Cao H, Liu C
Institution:Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
Journal:Elife. 2023 Feb 6;12:e83045. doi: 10.7554/eLife.83045.

17:Identifying recurrences and metastasis after ductal carcinoma in situ (DCIS) of the breast.
Authors:Udayasiri RI, Luo T, Gorringe KL, Fox SB
Institution:Peter MacCallum Cancer Centre and the Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
Journal:Histopathology. 2023 Jan;82(1):106-118. doi: 10.1111/his.14804.

18:Prognostic significance of microinvasion with ductal carcinoma in situ of the breast: a meta-analysis.
Authors:Shiino S, Quinn C, Ball G, Syed BM, Kurozumi S, Tsuda H, Rakha EA
Institution:Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham, UK. emad.rakha@nottingham.ac.uk.
Journal:Breast Cancer Res Treat. 2023 Jan;197(2):245-254. doi: 10.1007/s10549-022-06800-3. Epub 2022 Nov 24.

19:Oncological safety of active surveillance for low-risk ductal carcinoma in situ - a systematic review and meta-analysis.
Authors:Davey MG, Lowery AJ, Kerin MJ
Institution:Department of Surgery, The Lambe Institute for Translational Research, National University of Ireland, Galway, H91YR71, Ireland. mattgdavey1@gmail.com.
Journal:Ir J Med Sci. 2023 Aug;192(4):1595-1600. doi: 10.1007/s11845-022-03157-w. Epub 2022 Sep 16.

For a FREE PREVIEW of the Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast...
at a Special 25% Discount


Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast

Updated: January 11, 2024
124 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $39.95
  • Less 25% Discount = - $10.00
  • Discounted Price = $29.95(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $26.60
  • Less 25% Discount = - $6.65
  • Discounted Price = $19.95

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 25% discount when you order your Guidebook by phone.

To receive your 25% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

DC242050445

Coupon Expires: August 22, 2024



What Our Customers Are Saying...

"The MediFocus Guidebook on DCIS was more than adequate for my research on this condition and I would recommend it to anyone wanting the "whole picture". Thank you for providing this excellent service."
C.M.
Los Angeles, California


"At a very difficult time, your MediFocus Guidebook on Ductal Carcinoma in Situ helped our family make informed decisions. Thank you for your help!"
M.A.L.
Metarie, Louisiana


"I was recently diagnosed with DCIS and was looking everywhere for information to get myself educated. The MediFocus Guidebook was very helpful in clarifying everything for me. The information is so well organized that it makes it easy to read and understand. I feel much better now that I've read this Guidebook and have a clearer understanding of the issues that I face. I highly recommend this Guidebook to anyone seeking to understand DCIS."
C.G.
Ft. Lauderdale, Florida



  
Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2024 Medifocus, Inc. All rights reserved.